Skip to main content

Advertisement

SpringerLink
Log in

14-3-3 Protein beta/alpha as a urinary biomarker for renal cell carcinoma: proteomic analysis of cyst fluid

  • Original Paper
  • Published:
Analytical and Bioanalytical Chemistry Aims and scope Submit manuscript

Abstract

Although various samples, including tissue, cells, serum, and urine, from patients with renal cell carcinoma (RCC) have been analyzed, biomarkers with diagnostic value have yet to be identified. We used a proteomics approach to analyze cyst fluid in cases of cyst-associated RCC to identify accessible and abundant proteins that are overexpressed and/or secreted by RCC cells. Proteins in the cyst fluid were separated by reverse-phase high-performance liquid chromatography and agarose two-dimensional gel electrophoresis and were identified by tandem mass spectrometry. We conducted a National Center for Biotechnology Information search and a MEDLINE search to predict the function of these identified proteins and to select a tumor-marker candidate protein. Our search resulted in the identification and selection of the differentially regulated protein known as 14-3-3 protein beta/alpha, which was overexpressed in cyst fluid from cyst-associated RCC but has not been previously associated with RCC. We then measured its incidence through Western blotting of various normal and RCC samples (serum, urine, tissue, and cyst fluid). The expression levels of 14-3-3 protein beta/alpha were higher in urine samples from patients with RCC than in samples from healthy volunteers. Receiver operating characteristic (ROC) curve analyses were performed to assess this potential biomarker; these data (area under the ROC curve value was 0.8813) indicate a high degree of accuracy for this screening method. 14-3-3 Protein beta/alpha may be a diagnostically useful biomarker for early diagnosis of RCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Amato RJ (2005) Renal cell carcinoma: review of novel single agent therapeutics and combination regimens. Ann Oncol 16:7–15

    Article  CAS  Google Scholar 

  2. Hafez KS, Fergany AF, Novick AC (1999) Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol 162:1930–1933

    Article  CAS  Google Scholar 

  3. Patard JJ, Leray E, Cindolo L, Ficarra V, Rodriguez A, De La Taille A, Tostain J, Artibani W, Abbou CC, Guillé F, Chopin DK, Lobel B (2004) Multi-institutional validation of a symptom based classification for renal cell carcinoma. J Urol 172:858–862

    Article  Google Scholar 

  4. Pantuck AJ, Zisman A, Belldegrun A (2001) The changing natural history of renal cell carcinoma. J Urol 166:1611–1623

    Article  CAS  Google Scholar 

  5. Tunuguntla HS, Jorda M (2008) Diagnostic and prognostic molecular markers in renal cell carcinoma. J Urol 179:2096–2102

    Article  CAS  Google Scholar 

  6. Seliger B, Dressler SP, Lichtenfels R, Kellner R (2007) Candidate biomarkers in renal cell carcinoma. Proteomics 24:4601–4612

    Article  Google Scholar 

  7. Seliger B, Lichtenfels R, Atkins D, Bukur J, Halder T, Kersten M, Harder A, Ackermann A, Malenica B, Brenner W, Zobawa M, Lottspeich F (2005) Identification of fatty acid binding proteins as markers associated with the initiation and/or progression of renal cell carcinoma. Proteomics 10:2631–2640

    Article  Google Scholar 

  8. Tolson J, Bogumil R, Brunst E, Beck H, Elsner R, Humeny A, Kratzin H, Deeg M, Kuczyk M, Mueller GA, Mueller CA, Flad T (2004) Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest 84:845–856

    Article  CAS  Google Scholar 

  9. Kim DS, Choi YP, Kang S, Gao MQ, Kim B, Park HR, Choi YD, Lim JB, Na HJ, Kim HK, Nam YP, Moon MH, Yun HR, Lee DH, Park WM, Cho NH (2008) Panel of candidate biomarkers for renal cell carcinoma. J Proteome Res 7:3710–3719

    Google Scholar 

  10. Sarkissian G, Fergelot P, Lamy PJ, Patard JJ, Culine S, Jouin P, Rioux-Leclercq N, Darbouret B (2008) Identification of pro-MMP-7 as a serum marker for renal cell carcinoma by use of proteomic analysis. Clin Chem 54:574–581

    Article  CAS  Google Scholar 

  11. Gnarra JR, Lerman MI, Zbar B, Linehan WM (1995) Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. Semin Oncol 22:3–8

    CAS  Google Scholar 

  12. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M (2002) AJCC Cancer Staging Manual, 6th edn. Springer, New York

    Book  Google Scholar 

  13. Kawashima Y, Fukuno T, Satoh M, Takahashi H, Matsui T, Tadakazu M, Yoshio K (2009) A simple and highly reproducible method for discovering potential disease markers in low abundance serum proteins. J Electrophoresis 53:13–18

    Article  CAS  Google Scholar 

  14. Oh-Ishi M, Satoh M, Maeda T (2000) Preparative two-dimensional gel electrophoresis with agarose gels in the first dimension for high molecular mass proteins. Electrophoresis 21:1653–1669

    Article  CAS  Google Scholar 

  15. Yates JR 3rd, Eng JK, McCormack AL, Schieltz D (1995) Method to correlate tandem mass spectra of modified peptides to amino acid sequences in the protein database. Anal Chem 67:1426–1436

    Article  CAS  Google Scholar 

  16. Wulfkuhle JD, Paweletz CP, Steeg PS, Petricoin EF 3rd, Liotta L (2003) Proteomic approaches to the diagnosis, treatment, and monitoring of cancer. Adv Exp Med Biol 532:59–68

    Article  CAS  Google Scholar 

  17. Aitken A (2006) 14-3-3 Proteins: a historic overview. Semin Cancer Biol 16:162–172

    Article  CAS  Google Scholar 

  18. Rushworth LK, Hindley AD, O’Neill E, Kolch W (2006) Regulation and role of Raf-1/B-Raf heterodimerization. Mol Cell Biol 26:2262–2272

    Article  CAS  Google Scholar 

  19. Sunayama J, Tsuruta F, Masuyama N, Gotoh Y (2005) JNK antagonizes Akt-mediated survival signals by phosphorylating 14-3-3. J Cell Biol 170:295–304

    Article  CAS  Google Scholar 

  20. Tsuruta F, Sunayama J, Mori Y, Hattori S, Shimizu S, Tsujimoto Y, Yoshioka K, Masuyama N, Gotoh Y (2004) JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins. EMBO J 23:1889–1999

    Article  CAS  Google Scholar 

  21. Porter GW, Khuri FR, Fu H (2006) Dynamic 14-3-3/client protein interactions integrate survival and apoptotic pathways. Semin Cancer Biol 16:193–202

    Article  CAS  Google Scholar 

  22. Mils V, Baldin V, Goubin F, Pinta I, Papin C, Waye M, Eychene A, Ducommun B (2000) Specific interaction between 14-3-3 isoforms and the human CDC25B phosphatase. Oncogene 19:1257–1265

    Article  CAS  Google Scholar 

  23. Morrison DK (2009) The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol 19:16–23

    Article  CAS  Google Scholar 

  24. Moreira JM, Ohlsson G, Rank FE, Celis JE (2005) Down-regulation of the tumor suppressor protein 14-3-3sigma is a sporadic event in cancer of the breast. Mol Cell Proteomics 4:555–569

    Article  CAS  Google Scholar 

  25. Moreira JM, Gromov P, Celis JE (2004) Expression of the tumor suppressor protein 14-3-3sigma is down-regulated in invasive transitional cell carcinomas of the urinary bladder undergoing epithelial-tomesenchymal transition. Mol Cell Proteomics 3:410–419

    Article  CAS  Google Scholar 

  26. Lodygin D, Hermeking H (2005) The role of epigenetic inactivation of 14-3-3sigma in human cancer. Cell Res 15:237–246

    Article  CAS  Google Scholar 

  27. Vogelzang NJ, Stadler WM (1998) Kidney cancer. Lancet 352:1691–1696

    Article  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported in part by the Ministry of Education, Culture, Sports, Science, and Technology of Japan (No. 22591776).

Author information

Authors and Affiliations

  1. Department of Urology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa, 252–0374, Japan

    Satoru Minamida, Masatsugu Iwamura, Kenichi Tabata, Kazumasa Matsumoto, Tetsuo Fujita, Takefumi Satoh & Shiro Baba

  2. Department of Physics, Kitasato University School of Science, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa, 252–0374, Japan

    Yoshio Kodera, Yusuke Kawashima & Tadakazu Maeda

Authors
  1. Satoru Minamida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masatsugu Iwamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yoshio Kodera
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yusuke Kawashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kenichi Tabata
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kazumasa Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tetsuo Fujita
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takefumi Satoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tadakazu Maeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shiro Baba
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masatsugu Iwamura.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(PDF 984 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Minamida, S., Iwamura, M., Kodera, Y. et al. 14-3-3 Protein beta/alpha as a urinary biomarker for renal cell carcinoma: proteomic analysis of cyst fluid. Anal Bioanal Chem 401, 245–252 (2011). https://doi.org/10.1007/s00216-011-5057-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00216-011-5057-5

Keywords

Search

Navigation